A successful experimental model for intimal hyperplasia prevention using a resveratrol-delivering balloon

Journal of Vascular Surgery

Volumn 63, Issue 3, 2016, Pages 788-794

  Tolva, Valerio ^a,b   Mazzola, Silvia ^c   Zerbi, Pietro ^d   Casana, Renato ^a   Albertini, Mariangela ^c   Calvillo, Laura ^a   Selmin, Francesca ^c   Cilurzo, Francesco ^c  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RESVERATROL; BIOMATERIAL; CARDIOVASCULAR AGENT; STILBENE DERIVATIVE;

ADULT; ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROPHYLAXIS; PTCA CATHETER; VISCOSITY; ADVERSE EFFECTS; ANIMAL; CELL CULTURE; DEVICES; DISEASE MODEL; DRUG EFFECTS; EQUIPMENT DESIGN; HYPERPLASIA; INJURIES; NEOINTIMA; PATHOLOGY; RABBIT; SMOOTH MUSCLE CELL; VASCULAR ACCESS DEVICE; VASCULAR SMOOTH MUSCLE; VASCULAR SYSTEM INJURIES;

ANGIOPLASTY, BALLOON; ANIMALS; CARDIOVASCULAR AGENTS; CELL PROLIFERATION; CELLS, CULTURED; COATED MATERIALS, BIOCOMPATIBLE; DISEASE MODELS, ANIMAL; EQUIPMENT DESIGN; HUMANS; HYPERPLASIA; ILIAC ARTERY; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; RABBITS; STILBENES; VASCULAR ACCESS DEVICES; VASCULAR SYSTEM INJURIES;

EID: 84959538944     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2014.09.035     Document Type: Article

References (17)

1. G.M. Ansel, and A.B. Lumsden Evolving modalities for femoropopliteal interventions J Endovasc Ther 16 2009 82 97
2. P.J. Geraghty, M.W. Mewissen, M.R. Jaff, and G.M. Ansel VIBRANT Investigators. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease J Vasc Surg 58 2013 386 395
3. W. Casscells Migration of smooth muscle and endothelial cells. Critical events in restenosis Circulation 86 1992 723 729
4. B. Scheller, U. Speck, A. Schmitt, M. Bohm, and G. Nickenig Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation J Am Coll Cardiol 42 2003 1415 1420
5. M.B. Rosenbaum, K. Miyazaki, S.M. Colles, and L.M. Graham Antioxidant therapy reverses impaired graft healing in hypercholesterolemic rabbits J Vasc Surg 51 2010 184 193
6. J.J. Kleinedler, J.D. Foley, E.A. Orchard, and T.R. Dugas Novel nano-composites stent coating releasing resveratrol and quercetin reduces neointimal hyperplasia and promotes reendothelization J Control Re1ease 10 2012 27 33
7. A.R. Khandelwal, V.Y. Hebert, J.J. Kleinedler, L.K. Rogers, S.L. Ullevig, R. Asmis, and et al. Resveratrol and quercetin interact to inhibit neointimal hyperplasia in mice with a carotid injury J Nutr 142 2012 1487 1494
8. J. Zou, Y. Huang, K. Cao, G. Yang, H. Yin, J. Len, and et al. Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model Life Sci 68 2000 153 163
9. A. Csiszar, K. Smith, N. Labinskyy, Z. Orosz, A. Rivera, and Z. Ungvari Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition Am J Physiol Heart Circ Physiol 291 2006 H1694 H1699
10. H.J. Park, S.K. Jeong, S.R. Kim, S.K. Bae, W.S. Kim, S.D. Jin, and et al. Resveratrol inhibits Porphyromonas gingivalis lipopolysaccharide-induced endothelial adhesion molecule expression by suppressing NF-kappaB activation Arch Pharm Res 32 2009 583 591
11. J.S. Park, K.M. Kim, M.H. Kim, H.J. Chang, M.K. Baek, S.M. Kim, and et al. Resveratrol inhibits tumor cell adhesion to endothelial cells by blocking ICAM-1 expression Anticancer Res 29 2009 355 362
12. K. Inanaga, T. Ichiki, H. Matsuura, R. Miyazaki, T. Hashimoto, K. Takeda, and et al. Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis Hypertens Res 32 2009 466 471
13. A.S. Leger, A.L. Cochrane, and F. Moore Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine Lancet 1 1979 1017 1020
14. T. Walle, F. Hseish, M.H. DeLegge, J.R. Oatis, and U.K. Walle High absorption but very low biovailability of oral resveratrol in humans Drug Metab Dispos 32 2004 1377 1382
15. K.R. Patel, V.A. Brown, D.J. Jones, R.G. Britton, D. Hemingway, A.S. Miller, and et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients Cancer Res 70 2010 7392 7399
16. V. Aires, E. Limagne, A.K. Cotte, N. Latruffe, F. Ghiringhelli, and D. Delmas Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death Mol Nutr Food Res 57 2013 1170 1181
17. C. Herdeg, K. Gorhing-Frischholz, K.K. Haase, T. Geisler, C. Zurn, U. Hartmann, and et al. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation Circ Cardiovasc Interv 2 2009 294 301